Topic	Questions
Usual practice	Before we get into the specifics, I want to find out a bit more about your role as a pharmacist outside of the 3D Study. In particular, whether you are involved in medication reviews for patients? (Driven by cost or CCG targets or led by the practice? Face-to-face or computer led? Useful or not? Barriers, facilitators.) Can you tell me about the last time you were involved in medication reviews for a practice? (Typical?) How have you found working with practices? Have you been involved in medication reviews for patients with polypharmacy? (Driven by cost or CCG targets or led by the practice? Face-to-face or computer led? Useful or not? Barriers, facilitators.)
3D Study case patients (2–3 for each interview)	Before we go on to talk about the case study patients, can you tell me any thoughts you have about the medication reviews for the 3D Study? (Working with practices, doing the reviews, purpose, useful.) Can you have a read over the record for this patient and talk me through the process you might have gone through when you reviewed this patient’s medications? Recommendations (types of medicines stopped/started, purpose of stopping/starting them, for example, safety, pill burden, guidelines). Typical of other 3D reviews? Same as/different from usual practice? Reflect on whether the GP acted on the recommendations (typical?).
Any other issues	Any other issues you would like to raise?

3D Study = a multicentre, cluster-randomised controlled trial of an organisational intervention for people with multimorbidity.¹⁹ CCG = clinical commissioning group. EMIS = Egton Medical Information Systems.